The role of myeloid cells in cancer therapies

@article{Engblom2016TheRO,
  title={The role of myeloid cells in cancer therapies},
  author={Camilla Engblom and Christina Pfirschke and Mikael J. Pittet},
  journal={Nature Reviews Cancer},
  year={2016},
  volume={16},
  pages={447-462}
}
Recent clinical trials have demonstrated the ability to durably control cancer in some patients by manipulating T lymphocytes. These immunotherapies are revolutionizing cancer treatment but benefit only a minority of patients. It is thus a crucial time for clinicians, cancer scientists and immunologists to determine the next steps in shifting cancer treatment towards better cancer control. This Review describes recent advances in our understanding of tumour-associated myeloid cells. These cells… Expand

Paper Mentions

Interventional Clinical Trial
It is nowadays well established that the immune system can profoundly influence disease outcome in cancer patients. Increasing evidence is indeed showing that patients displaying… Expand
ConditionsAdvanced Renal Cell Carcinoma, Healthy, Metastatic Breast Cancer, (+3 more)
InterventionDiagnostic Test
Innate myeloid cells in the tumor microenvironment.
TLDR
The latest research that has identified and compared the importance of pro-tumor and immunosuppressive mechanisms that tumor infiltrating myeloid cells employ may help to develop totally novel therapies to boost contemporary cancer immunotherapy. Expand
Tumor-associated myeloid cells: diversity and therapeutic targeting.
TLDR
An overview of the recent literature on the ever-growing complexity of the biology of TAMs and TANs and the development of the most promising approaches to target these populations therapeutically in cancer patients is provided. Expand
Myeloid cell heterogeneity in cancer: not a single cell alike.
TLDR
This review summarizes the most recent advances in understanding about how the phenotype of tumor-associated macrophages, monocytes, neutrophils, myeloid-derived suppressor cells and dendritic cells is dictated by their ontogeny, activation status and localization. Expand
Tuning the Tumor Myeloid Microenvironment to Fight Cancer
The tumor microenvironment (TME) of diverse cancer types is often characterized by high levels of infiltrating myeloid cells including monocytes, macrophages, dendritic cells, and granulocytes. TheseExpand
Targeting tumor-associated macrophages to synergize tumor immunotherapy
TLDR
Recent studies investigating the involvement of TAMs in immune checkpoint inhibition, tumor vaccines and adoptive cell transfer therapies are summarized, and the therapeutic potential of targeting TAMs as an adjuvant therapy in tumor immunotherapies is discussed. Expand
Allies or Enemies—The Multifaceted Role of Myeloid Cells in the Tumor Microenvironment
TLDR
How distinct myeloid cell types can act as enemies of cancer cells by inducing or enhancing an existing immune response, while others act as strong allies, supporting tumor cells in their malignant growth and establishing an immune evasive TME is described. Expand
Cancer-Host Interactions Influencing Disease Progression and Therapy
TLDR
This work investigated long-range interactions between lung tumors and the bone, and newly link bone marrow stromal cells to distant tumor outgrowth via the production of bone marrowderived cells. Expand
Role and Therapeutic Implications of MDSCs in Sarcomas
TLDR
The known role of myeloid-derived suppressor cells (MDSCs) in creating an immunosuppressive state in the tumor microenvironment is explored and current issues with properly defining this heterogeneous continuum of cells with apparent context dependent phenotypic plasticity are highlighted. Expand
The role of dendritic cells in cancer.
TLDR
Current knowledge of the roles played by different DC subsets in human cancer and how these might be manipulated as new immunotherapeutics to improve CD8+ T cell-mediated immune responses are discussed, with a particular focus on the conventional type 1 DCs (cDC1). Expand
Delineating Pro-Angiogenic Myeloid Cells in Cancer Therapy
TLDR
This review article is intended to compile all the relevant information in the literature for improved understanding of angiogenic myeloid cells and their role in tumor refractoriness to cancer therapy. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 270 REFERENCES
Macrophages and therapeutic resistance in cancer.
TLDR
This review discusses the molecular/cellular pathways identified so far whereby macrophages mediate therapeutic responses and therapeutics impacting macrophage presence and/or bioactivity have shown promise in preclinical models and are now being evaluated in the clinic. Expand
The future of immune checkpoint therapy
TLDR
The way forward for this class of novel agents lies in the ability to understand human immune responses in the tumor microenvironment, which will provide valuable information regarding the dynamic nature of the immune response and regulation of additional pathways that will need to be targeted through combination therapies to provide survival benefit for greater numbers of patients. Expand
Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected.
TLDR
The most pertinent and controversial issues of MDSC biology and their role in promoting cancer progression are discussed and how these cells may be used in the clinic, both as prognostic factors and as therapeutic targets are highlighted. Expand
Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy.
TLDR
It is shown that autochthonous tumors that lacked T-cell infiltration and resisted current treatment options could be successfully sensitized to host antitumor T cell immunity when appropriately selected immunogenic drugs were used. Expand
Tumor-associated macrophages: from mechanisms to therapy.
TLDR
Therapeutic success in targeting these protumoral roles in preclinical models and in early clinical trials suggests that macrophages are attractive targets as part of combination therapy in cancer treatment. Expand
Role of macrophage targeting in the antitumor activity of trabectedin.
TLDR
It is demonstrated that trabectedin, a recently approved chemotherapeutic agent, induces rapid apoptosis exclusively in mononuclear phagocytes, and this unexpected property may be exploited in different therapeutic strategies. Expand
Neutrophils support lung colonization of metastasis-initiating breast cancer cells
TLDR
It is demonstrated that neutrophil-derived leukotrienes aid the colonization of distant tissues by selectively expanding the sub-pool of cancer cells that retain high tumorigenic potential and the efficacy of using targeted therapy against a specific tumour microenvironment component is revealed. Expand
Cancer immunotherapy via dendritic cells
TLDR
Dendritic cells are an essential target in efforts to generate therapeutic immunity against cancer owing to their ability to control both immune tolerance and immunity. Expand
The Emerging Understanding of Myeloid Cells as Partners and Targets in Tumor Rejection
TLDR
The hypothesis that the antigen-presenting compartment within tumor microenvironments may contain significant numbers of potent allies to be leveraged for immune-based tumor clearance is advanced. Expand
Immunogenic cell death in cancer therapy.
TLDR
It is postulate that ICD constitutes a prominent pathway for the activation of the immune system against cancer, which in turn determines the long-term success of anticancer therapies and its subversion by pathogens. Expand
...
1
2
3
4
5
...